Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655130 bioavailability study in healthy volunteers
NCT03617835Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2018
- Primary completion
- Jun 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of spesolimab (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 655130 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 4200 hours, Area Under the Concentration-time Curve of BI 655130 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Dose-Normalized at 4200 hours and 2 more. Started Aug 2018; status: completed.
02
Drugs
spesolimab
Beyond the preview
Go deeper on NCT03617835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617835.